<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1901233121
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARBAVAL 80 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VALSARTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        80
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        24.9
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SAJA-SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Arbaval&reg; belongs to a class of medicines known as angiotensin II receptor antagonist, which help to control high blood pressure. Angiotensin II is a substance in the body that causes vessels to tighten, thus causing your blood pressure to increase. Arbaval&reg; works by blocking the effect of angiotensin II. As a result, blood vessels relax and blood pressure is lowered.</p><p><strong>Arbaval&reg; 40 mg can be used for three different conditions:</strong></p><p>&bull;&nbsp;&nbsp; To treat high blood pressure in children and adolescents 6 to 18 years of age.</p><p>High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure.</p><p>High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>&bull;&nbsp;&nbsp; To treat adult patients after a recent heart attack (myocardial infarction). &quot;Recent&quot; here means between 12 hours and 10 days.</p><p>&bull;&nbsp;&nbsp;&nbsp; to treat symptomatic heart failure in adult patients. Arbaval<sup>&reg;</sup> is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid build-up. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Arbaval&reg; 80 mg can be used for three different conditions:</strong></p><p>&bull;&nbsp;&nbsp; To treat high blood pressure in adult and in children and adolescents 6 to 18 years of age. High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>&bull;&nbsp;&nbsp; To treat adult patients after a recent heart attack (myocardial infarction). &quot;Recent&quot; here means between 12 hours and 10 days.</p><p>&bull;&nbsp;&nbsp;&nbsp; To treat symptomatic heart failure in adult patients. Arbaval<sup>&reg;</sup> is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid buildup. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Arbaval&reg; 160 mg can be used for three different conditions:</strong></p><p>&bull;&nbsp;&nbsp; To treat high blood pressure in adult and in children and adolescents 6 to 18 years of age. High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p><p>&bull;&nbsp;&nbsp; To treat adult patients after a recent heart attack (myocardial infarction). &quot;Recent&quot; here means between 12 hours and 10 days.</p><p>&bull;&nbsp;&nbsp;&nbsp; To treat symptomatic heart failure in adult patients. Arbaval&reg; is used when a group of medicines called Angiotensin Converting Enzyme (ACE) inhibitors (a medication to treat heart failure) cannot be used. Heart failure symptoms include shortness of breath, and swelling of the feet and legs due to fluid buildup. It is caused when the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body.</p><p><strong>Arbaval 320 mg can be used</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; To treat high blood pressure in adults and in children and adolescents 6 to 18 years of age. High blood pressure increases the workload on the heart and arteries. If not treated it can damage the blood vessels of the brain, heart, and kidneys, and may result in a stroke, heart failure, or kidney failure. High blood pressure increases the risk of heart attacks. Lowering your blood pressure to normal reduces the risk of developing these disorders.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Arbaval<sup>&reg;</sup>:</strong></p><p>&bull;&nbsp;&nbsp; if you are allergic (hypersensitive) to Arbaval<sup>&reg;</sup> or any of the other ingredients of Arbaval<sup>&reg;</sup> listed at the end of this leaflet.</p><p>&bull;&nbsp;&nbsp; if you have severe liver disease.</p><p>&bull;&nbsp;&nbsp; if you are more than 3 months pregnant (it is also better to avoid Arbaval&reg; in early pregnancy - see pregnancy section).</p><p><strong>If any of these apply to you, do not take Arbaval&reg;</strong></p><p>Take special care with Arbaval&reg;:</p><p>&bull;&nbsp;&nbsp; if you have liver disease.</p><p>&bull;&nbsp;&nbsp; if you have severe kidney disease or if you are undergoing dialysis.</p><p>&bull;&nbsp;&nbsp; if you are suffering from a narrowing of the kidney artery.</p><p>&bull;&nbsp;&nbsp; if you have recently undergone kidney transplantation (received a new kidney).</p><p>&bull;&nbsp;&nbsp; if you are treated after a heart attack or for heart failure, your doctor may check your kidney function.</p><p>&bull;&nbsp;&nbsp; if you have severe heart disease other than heart failure or heart attack.</p><p>&bull;&nbsp;&nbsp;&nbsp; If you have ever experienced swelling of the tongue and face caused by an allergic reaction called angioedema when taking another drug (including ACE inhibitors), tell your doctor. If these symptoms occur when you are taking Arbaval&reg;, stop taking Arbaval immediately and never take it again. See also section&nbsp;4.&quot;Possible side effects&quot;.</p><p>&bull;&nbsp;&nbsp; if you are taking medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium sparing medicines and heparin. It may be necessary<sup> </sup>to check the amount of potassium in your blood at regular intervals.</p><p>&bull;&nbsp;&nbsp; if you are below 18 years of age and you take Arbaval&reg; in combination with other medicines that inhibit the renin angiotensin aldosterone system (medicines that lower blood pressure), your doctor may check your kidney function and the amount of potassium in your blood at regular intervals.</p><p>&bull;&nbsp;&nbsp;&nbsp; if you suffer from aldosteronism. This is a disease in which your adrenal glands make too much of the hormone aldosterone. If this applies to you, the use of Arbaval<sup>&reg;</sup> is not recommended.</p><p>&bull;&nbsp;&nbsp; if you have lost a lot of fluid (dehydration) caused by diarrhoea, vomiting, or high doses of water tablets (diuretics).</p><p>&bull;&nbsp;&nbsp; you must tell your doctor if you think you are (or might become) pregnant. Arbaval&reg; is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p><strong>If any of these apply to you, tell your doctor before you take Arbaval&reg;:</strong></p><p><strong>Taking other medicines</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.</p><p>The effect of the treatment can be influenced if Arbaval&reg; is taken together with certain other medicines. It may be necessary to change the dose, to take other precautions, or in some cases to stop taking one of the medicines. This applies to both prescription and non-prescription medicines, especially:</p><p>&bull;&nbsp;&nbsp; other medicines that lower blood pressure, especially water tablets (diuretics).</p><p>&bull;&nbsp;&nbsp; medicines that increase the amount of potassium in your blood. These include potassium supplements or salt substitutes containing potassium, potassium-sparing medicines and heparin.</p><p>&bull;&nbsp;&nbsp; certain type of pain killers called non-steroidal anti-inflammatory medicines (NSAIDs).</p><p>&bull;&nbsp;&nbsp; some antibiotics (Rifamycin group), a drug used to protect against transplant rejection (ciclosporin) or an antiretroviral drug used to treat HIV/AIDS infection (Ritonavir). These drugs may increase the effect of Arbaval&reg;.</p><p>&bull;&nbsp;&nbsp; Lithium, a medicine used to treat some types of psychiatric illness.</p><p><strong>In addition:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; if you are being treated after a heart attack, a combination with ACE inhibitors (a medication to treat heart attack) is not recommended.</p><p>&bull;&nbsp;&nbsp; if you are being treated for heart failure, a triple combination with ACE inhibitors and beta blockers (medications to treat heart failure) is not recommended.</p><p><strong>Taking Arbaval<sup>&reg;</sup> with food and drink</strong></p><p>You can take Arbaval<sup>&reg;</sup> with or without food.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&bull;&nbsp;&nbsp; You must tell your doctor if you think that you are (or might become) pregnant. Your doctor will normally advise you to stop taking Arbaval&reg; before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead of Arbaval&reg;. Arbaval is not recommended</p><p>in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p>&bull;&nbsp;&nbsp; Tell your doctor if you are breast-feeding or about to start breast-feeding. Arbaval<sup>&reg;</sup> is not recommended for mothers who are breastfeeding, and your doctor may choose another treatment for you if</p><p>you wish to breast-feed, especially if your baby is newborn, or was born prematurely</p><p><strong>Driving and using machines</strong></p><p>Before you drive a vehicle, use tools or operate machines, or carry out other activities that require concentration, make sure you know how Arbaval&reg; affects you. Like many other medicines used to treat high blood pressure, Arbaval&reg; may in rare cases cause dizziness and affect the ability to concentrate.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Arbaval&reg; exactly as your doctor has told you in order to get the best results and reduce the risk of side effects. You should check with your doctor or pharmacist if you are not sure. People with high blood pressure often do not notice any signs of this problem. Many may feel quite normal. This makes it all the more important for you to keep your appointments with the doctor even if you are feeling well.</p><p><strong>Adult patients with high blood pressure</strong>: The usual dose is 80 mg daily. In some cases, your doctor may prescribe higher doses (e.g. 160 mg or 320 mg). He may also combine Arbaval&reg; with an additional medicine (e.g. a diuretic).</p><p><strong>Children and adolescents (6 to 18 years of age) with high blood pressure:</strong></p><p>In patients who weigh less than 35 kg the usual dose is 40 mg of Arbaval&reg; once daily. In patients who weigh 35 kg or more the usual starting dose is 80 mg of Arbaval once daily. In some cases, your doctor may prescribe higher doses (the dose can be increased to 160 mg and to a maximum of 320 mg).</p><p><strong>Adult patients after a recent heart attack: </strong>After a heart attack the treatment is generally started as early as after 12 hours, usually at a low dose of 20 mg twice daily. You obtain the 20 mg dose by dividing the 40 mg tablet. Your doctor will increase this dose gradually over several weeks to a maximum of 160 mg twice daily.</p><p>The final dose depends on what you as an individual patient can tolerate. Arbaval&reg; can be given together with other treatment for heart attack, and your doctor will decide which treatment is suitable for you.</p><p><strong>Adult patients with heart failure:</strong> Treatment starts generally with 40 mg twice daily. Your doctor will increase the dose gradually over several weeks to a maximum of 160 mg twice daily. The final dose depends on what you as an individual patient can tolerate. Arbaval<sup>&reg;</sup> can be given together with other treatment for heart failure, and your doctor will decide which treatment is suitable for you.</p><p>You can take Arbaval<sup>&reg;</sup> with or without food.</p><p>Swallow Arbaval&reg; with a glass of water.</p><p>Take Arbaval<sup>&reg;</sup> at about the same time each day.</p><p>I<strong>f you take more Arbaval&reg; than you should</strong></p><p>If you experience severe dizziness and/or fainting, contact your doctor immediately and lie down. If you have accidentally taken too many tablets, contact your doctor, pharmacist, or hospital.</p><p><strong>If you forget to take Arbaval<sup>&reg;</sup></strong></p><p>If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next dose, skip the dose you missed.</p><p>Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Arbaval&reg;</strong></p><p>Stopping your treatment with Arbaval<sup>&reg;</sup> may cause your disease to get worse. Do not stop taking your medicine unless your doctor tells you to.</p><p>If you have further questions on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Arbaval&reg; can cause side effects, although not everybody gets them.</p><p>These side effects may occur with certain frequencies, which are defined as follows:</p><p>very common: affects more than 1 user in 10</p><p>common: affects 1 to 10 users in 100</p><p>uncommon: affects 1 to 10 users in 1,000</p><p>rare: affects 1 to 10 users in 10,000</p><p>very rare: affects less than 1 user in 10,000</p><p>not known: frequency cannot be estimated from the available data.</p><p><strong>Some symptoms need immediate medical attention:</strong></p><p>You may experience symptoms of angioedema (a specific allergic reaction), such as</p><p>&bull;&nbsp;&nbsp; Swollen face, lips, tongue or throat</p><p>&bull;&nbsp;&nbsp; Difficulty in breathing or swallowing</p><p>&bull;&nbsp;&nbsp; Hives, itching</p><p><strong>If you get any of these symptoms, stop taking Arbaval&reg; and contact your doctor straight away (see also section 2 &quot;Take special care with Arbaval &quot;).</strong></p><p><strong>Side effects Include:</strong></p><p>&bull;&nbsp;&nbsp; <strong>Common</strong></p><p>-&nbsp;&nbsp;&nbsp; Dizziness</p><p>-&nbsp;&nbsp;&nbsp; Low blood pressure with or without symptoms such as dizziness and fainting when standing up</p><p>-&nbsp;&nbsp;&nbsp; Decreased kidney function (signs of renal impairment)</p><p>&bull;&nbsp;&nbsp; <strong>Uncommon</strong></p><p>(see section &quot;Some symptoms need immediate medical attention&quot;)</p><p>-&nbsp;&nbsp;&nbsp; Sudden loss of consciousness (syncope)</p><p>-&nbsp;&nbsp;&nbsp; spinning sensation (vertigo)</p><p>-&nbsp;&nbsp;&nbsp; severely decreased kidney function (signs of acute renal failure)</p><p>-&nbsp;&nbsp;&nbsp; muscle spasms</p><p>-&nbsp;&nbsp;&nbsp; abnormal heart rhythm (signs of hyperkalaemia)</p><p>-&nbsp;&nbsp;&nbsp; breathlessness, difficulty breathing when lying down</p><p>-&nbsp;&nbsp;&nbsp; swelling of the feet or legs (signs of cardiac failure)</p><p>-&nbsp;&nbsp;&nbsp; headache, cough</p><p>-&nbsp;&nbsp;&nbsp; abdominal pain, nausea, diarrhea ,tiredness ,weakness</p><p><strong>&bull;&nbsp;&nbsp; Not known</strong></p><p>-&nbsp;&nbsp;&nbsp; Aller gic reactions with rash, itching and hives; symptoms of fever, swollen joints and joint pain, muscle pain, swollen lymph nodes and/or flu-like symptoms may occur (signs of serum sickness)</p><p>-&nbsp;&nbsp;&nbsp; Purplish-red spots, fever, itching (signs of inflammation of blood vessels also called vasculitis) unusual bleeding or bruising (signs of thrombocytopenia)</p><p>-&nbsp;&nbsp;&nbsp; Muscle pain (myalgia)</p><p>-&nbsp;&nbsp;&nbsp; Fever, sore throat or mouth ulcers due to infections (symptoms of low level of white blood cells also called neutropenia)</p><p>-&nbsp;&nbsp;&nbsp; Decrease of level of haemoglobin and decrease of the percentage of red blood cells in the blood (which can lead to anaemia in severe cases)</p><p>-&nbsp;&nbsp;&nbsp; Increase of level of potassium in the blood (which can trigger muscle spasms and abnormal heart rhythm in severe cases)</p><p>-&nbsp;&nbsp;&nbsp; Elevation of liver function values (which can indicate liver damage) including an increase of bilirubin in the blood (which can trigger yellow skin and eyes in severe cases)</p><p>-&nbsp;&nbsp;&nbsp; Increase of level of blood urea nitrogen and increase of level of serum creatinine (which can indicate abnormal kidney function)</p><p>-&nbsp;&nbsp;&nbsp; Low level of sodium in the blood (which can trigger tiredness, confusion, muscle twitching and/or convulsions in severe cases)</p><p><strong>The frequency of some side effects may vary depending on your condition. </strong>For example, side effects such as dizziness, and decreased kidney function, were seen less frequently in adult patients treated with high blood pressure than in adult patients treated for heart failure or after a recent heart attack.</p><p>-Side effects in children and adolescents are similar to those seen in adults.</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children</p><p>Store below &deg;30C.</p><p>Store in the original package in order to protect from moisture .</p><p>Do not use Arbaval<sup>&reg;</sup> after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull;&nbsp;&nbsp; The active substance is Valsartan</p><p>Each film-coated tablet contains 40 mg, 80 mg, 160 mg or 320 mg Valsartan</p><p>&bull; The other ingredients are Silicified microcrystalline cellulose, Crospovidone, Magnesium stearate &amp; Opadry pink.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                • Arbaval® 40 mg tablets are pink, film-coated tablets, ovaloid tablets that
are embossed with SJ325 on one side. Packs of 28 film-coated tablets
• Arbaval® 80 mg tablets are p ink, film-coated tablets round tablets that are
embossed with SJ327 on one side. Packs of 28 film-coated tablets
• Arbaval® 160 mg tablets are pink, film-coated tablets ovaloid tablets that
are embossed with SJ331 on one side. Packs of 28 film-coated tablets
)2 blisters, each blister has 14 Tablets(
• Arbaval® 320 mg tablets are pink, film-coated tablets, ovaloid with
embossed with SJ333 on one side. Packs of 28 film-coated tablets
)4 blisters, each blister has 7 tablets(
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>SAJA Pharmaceuticals</p><p>Saudi Arabian Japanese pharmaceutical company limited Jeddah - Saudi Arabia</p><p>&nbsp;</p><p><strong>--To report any side effect )s(<br />&bull; Saudi Arabia:</strong><br />- The National Pharmacovigilance Centre )NPC(:<br />- Fax: +966-11-205-7662<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa<br /><strong>&bull; Other GCC States / other countries:</strong><br />- Please contact the relevant competent authority.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July/2016-01
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ينتمي أربافال إلى مجموعة من الأدوية تُعرف بمناهضات مستقبلات الأنجيوتنسين &mdash; ٢، والتي تُساعد على التحكم في ارتفاع ضغط الدم. الأنجيوتنسين &mdash; ٢ هو مادة في الجسم تسبب انقباض الأوعية الدموية مما ينتج عنه ارتفاع في ضغط الدم لديك. يعمل أربافال من خلال تثبيط تأثير الأنجيوتنسين &mdash; ٢ ٠ وكنتيجة لذلك تسترخي الأوعية الدموية ويتم خفض ضغط الدم.</p><p dir="RTL"><strong>&nbsp;يمكن استخدام اربافال ٤٠ ملج لعلاج ثلاث حالات مختلفة:</strong></p><p dir="RTL">●&nbsp;&nbsp; لعلاج ارتفاع ضغط الدم في المرضي من الأطفال والمراهقين الذين تتراوح اعمارهم بين ٦ و١٨ سنة.</p><p dir="RTL">يزيد ارتفاع ضغط الدم من عبء العمل على القلب والشرايين. إذا لم يتم علاجه، يمكن ان يتسبب في تلف الأوعية الدموية في المخ والقلب والكليتين، وقد يؤدي إلى الإصابة بجلطة او هبوط (فشل) القلب او الفشل الكلوي. يزيد ارتفاع ضغط الدم من خطورة الإصابة بأزمات قلبية. يقلل انخفاض ضغط الدم لديك إلى المستوى الطبيعي من خطورة الإصابة بتك الأمراض.</p><p dir="RTL">●&nbsp;&nbsp; لعلاج المرضي من البالغين بعد الاصابة بأزمة قلبية حديثة (احتشاء عضلة القلب). كلمة &quot;حديثة&quot; هنا تعني ما بين ١٢ ساعة و١٠ ايام 12 .</p><p dir="RTL">●&nbsp;&nbsp;&nbsp; لعلاج هبوط القلب المصحوب بأعراض في المرضي من البالغين. يستخدم اربافال في حالة عدم إمكانية استخدام مجموعة من الأدوية تُعرف باسم مثبطات الإنزيم المحول للانجيوتنسين(ادوية تستخدم لعلاج هبوط القلب). تشمل اعراض هبوط القلب ضيق التنفس، وتورم القدمين والساقين بسبب تراكم السوائل. يحدث ذك عندما تكون عضلة القلب غير قادرة على ضخ الدم بقوة كافية لإمداد جميع اجزاء الجسم بكمية الدم المطلوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استخدام اربافال ٨٠ ملج لعلاج ثلاث&nbsp; حالات مختلفة:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp; لعلاج ارتفاع ضغط الدم في المرضي من البالغين وفي الاطفال والمراهقين الذين تتراوح اعمارهم بين ٦ و٨ ١ سنة. يزيد ارتفاع ضغط الدم من عبء العمل على القلب والشرايين. إذا لم يتم علاجه، يمكن ان يتسبب في تلف الأوعية الدموية في المخ والقلب والكليتين، وقد يؤدي إلى الإصابة بجلطة او هبوط القلب او الفشل الكلوي. يزيد ارتفاع ضغط من خطورة الإصابة بأزمات قلبية. يقلل انخفاض ضغط الدم لديك إلى المستوى الطبيعي من خطورة الإصابة بتلك الأمراض.</p><p dir="RTL">●&nbsp;&nbsp; لعلاج المرضي من البالغين&nbsp; بعد الاصابة بأزمة قلبية حديثة (احتشاء عضلة القلب). كلمة &quot;حديثة&quot; هنا تعني ما بين ١٢ ساعة و١٠ ايام.</p><p dir="RTL">لعلاج هبوط القلب المصحوب بأعراض في المرضي من البالغين. يُستخدم اربافال في حالة عدم إمكانية استخدام مجموعة من الأدوية تُعرف باسم مثبطات الإنزيم المحول للانجيوتنسين(ادوية تستخدم لعلاج هبوط القلب). تشمل اعراض هبوط القلب ضيق التنفس، وتورم القدمين والساقين بسبب تراكم السوائل. يحدث ذك عندما تكون عضلة القلب غير قادرة على ضخ الدم بقوة كافية لإمداد جميع اجزاء الجسم بكمية الدم المطلوبة.</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استخدام اربافال ١٦٠ ملج لعلاج ثلاث&nbsp; حالات مختلفة:</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp; لعلاج ارتفاع ضغط الدم في المرضي من البالغين وفي الاطفال والمراهقين الذين تتراوح اعمارهم بين ٦ و٨ ١ سنة. يزيد ارتفاع ضغط الدم من عبء العمل على القلب والشرايين. إذا لم يتم علاجه، يمكن ان يتسبب في تلف الأوعية الدموية في المخ والقلب والكليتين، وقد يؤدي إلى الإصابة بجلطة او هبوط القلب او الفشل الكلوي. يزيد ارتفاع ضغط من خطورة الإصابة بأزمات قلبية. يقلل انخفاض ضغط الدم لديك إلى المستوى الطبيعي من خطورة الإصابة بتلك الأمراض.</p><p dir="RTL">●&nbsp;&nbsp; لعلاج المرضي من البالغين&nbsp; بعد الاصابة بأزمة قلبية حديثة (احتشاء عضلة القلب). كلمة &quot;حديثة&quot; هنا تعني ما بين ١٢ ساعة و١٠ ايام.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp; لعلاج هبوط القلب المصحوب بأعراض في المرضي من البالغين. يُستخدم اربافال في حالة عدم إمكانية استخدام مجموعة من الأدوية تُعرف باسم مثبطات الإنزيم المحول للانجيوتنسين(ادوية تستخدم لعلاج هبوط القلب). تشمل اعراض هبوط القلب ضيق التنفس، وتورم القدمين والساقين بسبب تراكم السوائل. يحدث ذك عندما تكون عضلة القلب غير قادرة على ضخ الدم بقوة كافية لإمداد جميع اجزاء الجسم بكمية الدم المطلوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن استخدام اربافال ٣٢٠ ملج</strong></p><p dir="RTL">لعلاج ارتفاع ضغط الدم في البالغين وفي الاطفال والمراهقين الذين تتراوح اعمارهم بين ٦ و٨ ١ سنة. يزيد ارتفاع ضغط الدم من عبء العمل على القلب والشرايين. إذا لم يتم علاجه، يمكن ان يتسبب في تلف الأوعية الدموية في المخ والقلب والكليتين، وقد يؤدي إلى الإصابة بجلطة او فشل القلب او الفشل الكلوي. يزيد ارتفاع ضغط من خطورة الإصابة بأزمات قلبية. يقلل انخفاض ضغط الدم لديك إلى المستوى الطبيعي من خطورة الإصابة بتلك الأمراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول اربافال في الحالات الأتية:</strong></p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تعاني من الحساسية (او فرط الحساسية) تجاه أربافال او أي من مكونات أربافال الأخرى المدرجة في نهاية هذه النشرة؛.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت مصابا بمرض<strong> </strong>شديد في الكبد<strong>.</strong></p><p dir="RTL">●&nbsp;&nbsp; إذا كنت حاملا لأكثر من ٣ اشهر (يُفضل ايضا تجنب تناول أربافال في بداية الحمل- راجعي قسم (الحمل)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;لا تتناول اربافال إذا انطبق عيه اي مما يلي</strong></p><p dir="RTL"><strong>اتخذ حذرا خاصاً مع اربافال في الحالات التالية:</strong></p><p dir="RTL">●&nbsp;&nbsp; إذا كنت مصابا بمرض في الكبد.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت مصابا ممرض شديد بالكلى، او إذا كنت تخضع للغسيل الكلوي.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تعاني من ضيق في الشريان الكلوي.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت قد خضعت مؤخرا لعملية زراعة الكلى (تلقيت زرع لكلية جديدة).</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تخضع للعلاج بعد ازمة قلبية او من هبوط القلب، قد يقوم طبيبك بفحص وظائف الكلى لديك.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تعاني من مرض شديد بالقلب بخلاف هبوط القلب او الأزمة القلبية.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت قد عانيت قبل ذلك من تورم اللسان والوجه بسبب رد فعل تحسسي يُسمي وذمة وعائية عند تناول عقار آخر (بما في لك مثبطات الإنزيم المحول للانجيوتنسين)، اخبر طبيبك. إذا حدثت تلك الأعراض اثناء تناولك لأربافال، توقف عن تناول اربافال على الفور ولا تتناوله مرة اخرى. راجع ايضا قسم ٤ &quot;الاعراض الجانبية &quot;.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تتناول ادوية لترفع مستويات البوتاسيوم لديك في الدم. تشمل هذه الأدوية مكملات البوتاسيوم او بدائل الملح المحتوية على البوتاسيوم، والأدوية الموفرة للبوتاسيوم والهيبارين. قد يكون من الضروري فحص مستوى البوتاسيوم لديك في الدم على فترات منتظمة.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تبلغ من العمر اقل من ١٨ عاما وكنت تتناول اربافال بمصاحبة ادوية اخرى تثبط من نظام الرينين -انجيوتنسين- الدوستيرون (ادوية تقوم بخفض ضغط الدم)، قد يقوم طبيبك بفحص وظائف الكلى لديك ومستوى البوتاسيوم لديك على فترات منتظمة .</p><p>●&nbsp;&nbsp; إذا كنت تعاني من الألدوستيرونية(فرط إفراز الألدوستيرون). وهو مرض تقوم فيه الغدد الكظرية بإنتاج كميات كبيرة جدا من هرمون الدوستيرون. إذا كانت هذه هي حالتك، ننصح بعدم استخدام أربافال.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت قد فقدت الكثير من السوائل (الجفاف) بسبب الإسهال، القيء، او جرعات كبيرة من الأقراص المدرة للبول (مدرات البول).</p><p dir="RTL">●&nbsp;&nbsp; يجب عليك إبلاع الطبيب الخاص بك، إذا كنتِ تعتقدين انك حامل (او قد تصبحين كذلك). لا يوصى باستخدام اربافال في بداية الحمل، ويجب عدم تناوله إذا كنت قد امضيت اكتر من ٣ اشهر في الحمل، حيت إنه قد يسبب اضرارا بالغة لطفلك إذا تم استخدامه في هذه المرحلة(راجعي قسم &quot;الحمل&quot;).</p><p dir="RTL"><strong>اخبر طبيبك قبل تناول اربافال إذا انطبق عليه اي مما يلي: </strong></p><p dir="RTL"><strong>تناول ادوية اخرى</strong></p><p dir="RTL">برجاء إبلاع الطبيب او الصيدلي الخاص بك إذا كنت تتناول او تناولت مؤخرا اية ادوية اخرى بما في ذلك الأدوية التي حصلت عليها بدون وصفة طبية (الأدوية اللا وصفية).</p><p dir="RTL">قد يتأثر اداء العلاج في حبة تناول اربافال مع ادوية اخرى معينة. قد يكون من الضروري تغيير الجرعة او اتخاذ احتياطات اخرى او في بعض الحالات وقف تناول احد الأدوية. ينطبق ذلك على الأدوية بوصفة طبية او بدون وصفة طبية على حد سواء، وخاصة:</p><p dir="RTL">●&nbsp;&nbsp; الأدوية الأخرى التي تعمل على خفض ضغط الدم، خاصة مدرات البول</p><p dir="RTL">●&nbsp;&nbsp; الأدوية التي تعمل على زيادة مستوى البوتاسيوم في دمك. تشمل هذه الأدوية مكملات البوتاسيوم او بدائل الملح المحتوية على البوتاسيوم، والأدوية<strong> </strong>الموفرة للبوتاسيوم والهيبارين.</p><p dir="RTL">●&nbsp;&nbsp; اخذ انواع معينة من المسكنات التي تعرف بمضادات الالتهاب غير الستيرويدية (NSAIDs)</p><p dir="RTL">●&nbsp;&nbsp; بعض المضادات الحيوية (مجموعة الريفاميسين)، عقار يُستخدم للوقاية من رفض الجسم للعضو المزروع (سيكلوسبورين) او أحد مضادات الفيروسات القهقرية المستخدمة في علاج عدوى فيروس نقص المناعي البشري/ الإيدز (ريتونافير). هذه الأدوية قد تزيد من تتير أربافال٠</p><p dir="RTL">●&nbsp;&nbsp;&nbsp; الليثيوم، دواء يستخدم لعلاج بعض انواع الأمراض النفسية.</p><p dir="RTL"><strong>بالإضافة إلى ذلك:</strong></p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تخضع للعلاج بعد أزمة قلبية لا يوصى الجمع بين مثبطات الالم المحول لاغجيوتنسين (ادوية تستخدم لعلاج الأزمة القلبية) وأربافال.</p><p dir="RTL">●&nbsp;&nbsp; إذا كنت تخضع للعلاج من هبوط القلب، لا يوصى بالجمع الثلاتي بين مثبطات الإنزيم المحول لهجيوتنسين وحاصرات بيتا (ادوية تُستخدم لعلاج هبوط القلب) واربافال ٠</p><p dir="RTL"><strong>تناول اربافال مع الطعام والشراب</strong><strong> </strong></p><p dir="RTL">يمكنك تناول اربافال مع الطعام بدونه.</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL">استشيري الطبيب او الصيدلي الخاص بك، قبل تناول اي دواء.</p><p dir="RTL">●&nbsp;&nbsp;&nbsp; يجب عليه إبلاغ الطبيب الخاص به إذا كنتٍ. تعتقدين انك حامل (اوقد تصبحين كذلك). سينصحك طبيبك عادة بوقف تناول اربافال قبل الحمل او بمجرد معرفتكِ بالحمل وسينصحك بتناول ادوية اخرى بدلا من اربافال. لا يوصى باستخدام اربافال في بداية الحمل، ويجب عدم تناوله إذا كنت قد امضيتا اكتر من ٣ اشهر في الحمل، حيث إنه قد يسبب اضرارا بالغة لطفلك إذا تم استخدامه بعد الشهر الثالث من الحمل.</p><p dir="RTL">●&nbsp;&nbsp; اخبري طبيبك إذا كنتِ مرضعاً او على وشك البدء في الرضاعة. لا يوصى باستعمال الأمهات المرضعات لاربافال، وقد يختار لكِ طبيبك علاجا آخر إذا كنت ترغبين في الإرضاع، خاصة إذا كان طفلك حديث الولادة او مبسترا.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قبل ممارسة القيادة، او استخدام الآلات او تشغيل الماكينات، او القيام بالأنشطة الأخرى التي تتطلب الانتباه، تأكد من معرفة كيفية تأثير اربافال عليك. مثله كمثل العديد من الأدوية الأخرى المستخدمة لعلاج ارتفاع ضغط الدم، قد يسبب اربافال، في حالات نادرة، الدوخة ويؤثر في القدرة على التركيز.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناؤل اربافال دائما وفقا للجرعة التي وصفها لك الطبيب او الصيدلي الخاص بك بالضبط للحصول على افضل النتائج ولتقليل خطر حدوت الاعراض الجانبية. يجب استشارة الطبيب او الصيدلي الخاص بك إذا لم تكن متأكدا من كيفية التناول. المرضى الذين يعانون من ارتفاع ضغط الدم لا يلاحظون غالباً اية علامات لهذه المشكلة قد يشعر العديد من الأشخاص<strong> </strong>بأنهم بصحة طبيعية تماما. يجعل هذا الأمر اكثر اهمية بالنسبة لك للحفاظ على مواعيدك مع طبيبك حتى في حالة إحساسك بتحسن.</p><p dir="RTL"><strong>المرضي من البالغين المصابين بارتفاع ضغط الدم:</strong> الجرعة المعتادة هي ٨٠ ملج يومياً. في بعض الحالات قد يصف لك طبيبك جرعات اعلى (١٦٠ ملج او ٣٢٠ ملج على سبيل المثال). يمكن ايضا الجمع بين اربافال واحد الأدوية الإضافية (مثل احد مدرات البول).</p><p dir="RTL"><strong>الأطفال والمراهقون (٦ إلى ١٨ سنة) المصابون بارتفاع ضغط الدم:</strong></p><p dir="RTL">في حالة المرضى الذين تقل اوزانهم عن ٣٥ كلج، الجرعة المعتادة هي ٤٠ ملج من اربافال مرة واحدة يومياً. في بعض المرضي الذين تبلغ اوزانهم ٣٥ كلج او اكتر، فان جرعة البدء المعتادة هي ٨٠ ملج من اربافال مرة واحدة يومياً. في بعض الحالات قد يصف لك طبيبك جرعات اعلى (يمكن زيادة الجرعة إلى ١٦٠ ملج وإلى ٣٢٠ ملج كحد أقصي).</p><p><strong>المرضى البالغون بعد أزمة قلبية حديثة</strong>: بعد الأزمة القلبية، يبدأ العلاج عامة في اقرب وقت عادة خلال الـ١٢ ساعة الأولى، وعادة بجرعة منخفضة تبلغ ٢٠ ملج مرتين يومي. يمكن الحصول على جرعة ٢٠ ملج من خلال تقسيم قرص ٤٠ ملج. يقوم طبيبك بزيادة هذه الجرعة تدريجياً على مدار عدة اسابيع للوصول إلى ١٦٠ ملج كحد اقصى مرتين يومياً. تعتمد الجرعة النهائية على مدى تحمل كل مريض. ممكن إعطاء اربافال بالتزامن مع علاج آخر للازمة القلبية، وسيقرر طبيبك العلاج المناسب لك</p><p dir="RTL"><strong>المرضى البالغون المصابون بهبوط (فشل) القلب: </strong>يبدا العلاج عادة بجرعة ٤٠ ملج مرتين يومياً. يقوم طبيبك بزيادة الجرعة تدريجياً على مدار عدة اسابيع للوصول إلى ١٦٠ ملج كحد اقصى مرتين يومياً. تعتمد الجرعة النهائية على مدى تحمل كل مريض. ممكن إعطاء اربافال بالتزامن مع علاج آخر لهبوط القلب، وسيقرر طبيبك العلاج المناسب لك</p><p dir="RTL">●&nbsp;&nbsp; يمكنك تناول اربافال مع الطعام او بدونه.</p><p dir="RTL">●&nbsp;&nbsp; قم بابتلاع اقراص اربافال بكوب من الماء.</p><p dir="RTL">●&nbsp;&nbsp; تناول اربافال في نفس الوقت من كل يوم.</p><p dir="RTL"><strong>إذا تناولت كمية من اربافال اكثر مما يجب</strong></p><p dir="RTL">إذا واجهتك دوخة شديدة و/او إغماء، اتصل بطبيبك على الفور واستلق. إذا تناولت الكثير جدا من الأقراص بدون قصد، اتصل بطبيبك او الصيدلي او المستشفى.</p><p dir="RTL"><strong>&nbsp;إذا نسيت تناول اربافال</strong></p><p dir="RTL">إذا نسيت تناول جرعة، فتناولها بمجرد تذكرها. مع ذلك، إذا كنت على وشك تناول الجرعة التالية، فتجاوز الجرعة المنسية.</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة نسيتها</p><p dir="RTL"><strong>إذا توقفت عن تناول اربافال</strong></p><p dir="RTL">قد يُسبب وقف العلاج باربافال تفاقم حلتك. لا تتوف عن تناول الدواء حتى يخبرك طبيبك بذلك.</p><p dir="RTL">إذا كانت لديك اسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب او الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، يمكن ان يُسبب اربافال اعراض جانبية، على الرغم من عدم حدوثها للجميع.</p><p dir="RTL">&nbsp;قد تحدث هذه الاعراض الجانبية بمعدلات تكرار معينة، وهي محددة على النحو التالي:</p><p dir="RTL">&nbsp;شائعة جدا: تؤثر على اكتر من مستخدم واحد من بين كل ١٠ مستخدمين.</p><p dir="RTL">شائعة: تؤثر على ١ إلى ١٠ مستخدمين من بين كل 100مستخدم.</p><p dir="RTL">غير شائعة: تؤثر على ١ إلى ١٠ مستخدمين من بين كل 1000مستخدم.</p><p dir="RTL">نادرة: تؤثر على ١ إلى ١٠ مستخدمين من بين كل 10000 مستخدم.</p><p dir="RTL">&nbsp;نادرة جدا: تؤثر على اقل من مستخدم واحد من بين كل 100000 مستخدم.</p><p dir="RTL">غير معروفة: لا يمكن تقدير معدل تكرار من واقع البيانات المتاحة.</p><p dir="RTL"><strong>بعض الأعراض التي تتطلب رعاية طبية عاجلة:</strong></p><p dir="RTL">&nbsp;قد تواجه اعراض وذمة وعائية (تفاعل حساسية معين)، مثل:</p><p dir="RTL">●&nbsp;&nbsp; تورم الوجه او الشفتين او اللسان او الحلق.</p><p dir="RTL">●&nbsp;&nbsp; صعوبة في التنفس او البلع.</p><p dir="RTL">●&nbsp;&nbsp; الشرى والحكة.</p><p dir="RTL"><strong>إذا واجهت أيا من تلك الأعراض، توقف عن تناول اربافال واتصل بطبيبك على الفور (راجع ايضاً قسم ٢ &quot;اتخذ حذرا خاصاً مع اربافال&quot;)</strong></p><p dir="RTL"><strong>&nbsp;تشمل الاعراض الجانبية:</strong></p><p dir="RTL"><strong>●&nbsp;&nbsp; اعراض جانبية شائعة</strong></p><p dir="RTL">●&nbsp;&nbsp; دوخة</p><p dir="RTL">●&nbsp;&nbsp; انخفاض ضغط الدم المصحوب او غير المصحوب بأعراض مثل الدوخة والإغماء عند النهوض.</p><p dir="RTL">●&nbsp;&nbsp; انخفاض وظائف الكلى (علامات قصور وظائف الكلى).</p><p dir="RTL"><strong>●&nbsp;&nbsp; اعراض جانبية غير شائعة</strong></p><p dir="RTL">(راجع قسم: &quot;بعض الأعراض التي تتطلب رعاية طبية عاجلة&quot;)</p><p dir="RTL">●&nbsp;&nbsp; فقدان مفاجئ للوعي (إغماء).</p><p dir="RTL">●&nbsp;&nbsp; إحساس بالدوران (دوار).</p><p dir="RTL">●&nbsp;&nbsp; انخفاض شديد في وظائف الكلى (علامات قصور كلوي شديد).</p><p>●&nbsp;&nbsp; تقلصات بالعضلات.</p><p dir="RTL">●&nbsp;&nbsp; اضطراب النظم القلبي (علامات فرط بوتاسيوم الدم).</p><p dir="RTL">●&nbsp;&nbsp; عسر التنفس، صعوبة التنفس عند الاستلقاء</p><p dir="RTL">●&nbsp;&nbsp; تورم الساقين او القدمين (علامات هبوط القلب).</p><p dir="RTL">●&nbsp;&nbsp; الصداع، السعال.</p><p dir="RTL">●&nbsp;&nbsp; الم بالبطن، غثيان، إسهال، إجهاد، ضعف.</p><p dir="RTL"><strong>●&nbsp;&nbsp; اعراض جانبية غير معروفة</strong></p><p dir="RTL">●&nbsp;&nbsp;&nbsp; قد تحدث ردود افعال تحسسية مصحوبة بطفح، وحكة وشرى؛ اعراض حمى، تورم المفاصل والم المفاصل، الم بالعضلات، تورم الغد الليمفاوية و/او اعراض تشبه الأنفلونزا(علامات مرض بالدم).</p><p dir="RTL">●&nbsp;&nbsp; بقع ارجوانية حمراء، حمى، حكة (علامات التهاب الأوعية الدموية المسماة ايضا التهاب الأوعية) نزيف غير معتاد او كدمات (علامات نقص الصفيحات الدموية).</p><p dir="RTL">●&nbsp;&nbsp; الم بالعضلات (الم عضلي).</p><p dir="RTL">●&nbsp;&nbsp; حمى، احتقان الحلق، او تقرحات بالفم بسبب العدوى(علامات انخفاض مستوى خلايا الدم البيضاء المسمي ايضا بنقص خلايا العدلات).</p><p dir="RTL">●&nbsp;&nbsp; انخفاض مستوى الهيموجلوبين وانخفاض نسبة خلايا الدم الحمراء في الدم (والتي ممكن ان تؤدي إلى فقر الدم في الحالات الشديدة).</p><p dir="RTL">●&nbsp;&nbsp; ارتفاع مستوى البوتاسيوم في الدم (والذي يمكن ان يتير تشنجات العضلات واضطراب النظم القلبي في الحالات الشديد؛).</p><p dir="RTL">●&nbsp;&nbsp;&nbsp; ارتفاع قيم وظائف الكبد (والذي يمكن ان يشير إلى تلف الكبد) بما في ذك زيادة مستوى البيليروبين في الدم (والذي يمكن ان يحفز اصفرار الجلد والعينين في الحالات الشديدة).</p><p dir="RTL">●&nbsp;&nbsp; ارتفاع مستوى اليوريا والنيتروجين في الدم وارتفاع مستوى الكرياتينين في الدم (والذي يمكن ان يشير إلى وظائف كلى غير طبيعية).</p><p dir="RTL">●&nbsp;&nbsp; انخفاض مستوى الصوديوم في الدم (والذي يمكن ان يثير الإجهاد، الارتباك، الارتعاش و/او تقلصات العضلات في الحالات الشديدة).</p><p dir="RTL">قد يختلف تكرار بعض الاعراض الجانبية وفقا لحالتك. على سبيل المثال، تمت ملاحظة الاعراض الجانبية مثل: الدوخة، وانخفاض وظائف الكلى بشكل اقل تكرارا في المرضى البالغين الذين يعالجون من ارتفاع ضغط الدم عن المرضى البالغين الذين يعالجون من هبوط القلب او بعد ازمة قلبية حديثة.</p><p dir="RTL">●&nbsp;&nbsp; الاعراض الجانبية التي تمت ملاحظتها في الأطفال والمراهقين مماثلة لأعراض التي تمت ملاحظتها لدى البالغين.</p><p dir="RTL"><strong>إذا اصبحت اي من الاعراض الجانبية خطيرة، او لاحظت اية اعراض جانبية غير مدرجة في هذه النشرة، يرجى إبلاغ طبيبك او الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيداً عن متناول ورؤية الأطفال.</p><p dir="RTL">&nbsp;يُحفظ في درجة حرارة أقل من ٣٠ درجة مئوية.</p><p dir="RTL">قم بتخزين الدواء في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">لا تستخدم اربافال بعد تاريخ انتهاء الصلاحية المدون على العبوة. يُشير تاريخ انتهاء صلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">يجب عدم التخلص من الأدوية عن طريق مياه الصرف او مع المخلفات المنزلية. استشير الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد تلك الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">●&nbsp;&nbsp; المادة الفعالة هي فالسارتان</p><p dir="RTL">يحتوي كل قرص مغلف على ٤٠ ملج، او ٨٠ ملج، او ١٦٠ ملج او ٣٢٠ ملج فالسارتان.</p><p dir="RTL">● المكونـات الأخـرى هـي سـليلوز دقيـق التبلور مشـبع بالسـليكا، كروسـبوفيدون، سـتيرات الماغنسـيوم،<br />اوبادري وردي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; أربافـال 4٠ملـج هـي أقـراص مغلفـة بيضاويـة الشـكل ورديـة اللـون منقـوش عليهـا &quot; &quot; SJ325علـى<br />احـد الجانبيـن.<br />&bull; أربافـال ٨٠ملـج هـي أقـراص مغلفـة مسـتديرة الشـكل ورديـة اللـون منقـوش عليهـا &quot; &quot; SJ327علـى<br />احـد الجانبيـن.<br />&bull; أربافــال 16٠ملــج هــي أقــراص مغلفــة بيضاويــة الشــكل ورديــة اللــون منقــوش عليهــا &quot; &quot; SJ331<br />علــى احــد الجانبيــن.<br /><strong>تحتوي العبوة على 2٨قرصا مغلفا (شريطين, كل شريط يحوي 14قرصا)</strong><br />&bull; أربافــال 32٠ملــج هــي أقــراص مغلفــة بيضاويــة الشــكل ورديــة اللــون منقــوش عليهــا &quot; &quot; SJ333<br />علــى احــد الجانبيــن.<br /><strong>تحتوي العبوة على 2٨قرصا مغلفا ( 4شرائط, كل شريط يحوي 7أقراص</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مصنع ساجا للصناعات الدوائية</p><p dir="RTL">الشركة العربية السعودية اليابانية للمنتجات الصيدلانية المحدودة</p><p dir="RTL">جدة - المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:<br />&bull; المملكة العربية السعودية</strong><br />- المركز الوطني للتيقظ والسلامة الدوائية<br />+966-11-2٠5-7662 :- فاكس<br />- مركز اتصال هيئة الغذاء والدواء : 19999<br />npc.drug@sfda.gov.sa :- البريد الإلكتروني<br />https://ade.sfda.gov.sa :- الموقع الإلكتروني<br /><strong>&bull; دول الخليج الأخرى/ الدول الأخرى</strong><br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل دولة<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو/ 2016-01
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbaval 40 mg film-coated tablets
Arbaval 80 mg film-coated tablets
Arbaval 160 mg film-coated tablets
Arbaval 320 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One film-coated tablet contains 40 mg of Valsartan.
One film-coated tablet contains 80 mg of Valsartan .One film-coated tablet contains 160 mg of Valsartan .
One film-coated tablet contains 320 mg of Valsartan .
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arbaval 40 mg film-coated tablets are pink, ovaloid tablets that are embossed with
SJ325 on one side.
Arbaval 80 mg film-coated tablets are pink, round tablets that are embossed with
SJ327 on one side.
Arbaval 160 mg film-coated tablets are pink, ovaloid tablets that are embossed with
SJ331 on one side.
Arbaval 320 mg film-coated tablets are pink, ovaloid with embossed with SJ333 on one
side
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension (only 40 mg)</p><p>Treatment of hypertension in children and adolescents 6 to 18 years of age. Hypertension (only 80 mg, 160 mg and 320 mg)</p><p>Treatment of essential hypertension in adults, and hypertension in children and adolescents 6 to 18 years of age.</p><p>Recent myocardial infarction (only 40 mg, 80 mg and 160 mg)</p><p>Treatment of clinically stable adult patients with symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hours-10 days) myocardial infarction.</p><p>Heart failure (only 40 mg, 80 mg and 160 mg)</p><p>Treatment of symptomatic heart failure in adult patients when Angiotensin Converting Enzyme (ACE) inhibitors cannot be used</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Posology</p><p><strong>Hypertension (only 80 mg, 160 mg and 320 mg)</strong></p><p>The recommended starting dose of Arbaval is 80 mg once daily. The antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks. In some patients whose blood pressure is not adequately controlled, the dose can be increased to 160 mg and to a maximum of 320 mg.</p><p>Arbaval may also be administered with other antihypertensive agents. The addition of a diuretic such as hydrochlorothiazide will decrease blood pressure even further in these patients.</p><p>Recent myocardial infarction (only 40 mg, 80 mg and 160 mg)</p><p>&nbsp;</p><p>In clinically stable patients, therapy may be initiated as early as 12 hours after a myocardial infarction. After an initial dose of 20 mg twice daily, Arbaval&nbsp;&nbsp; should be titrated to 40 mg, 80 mg, and 160 mg twice daily over the next few weeks. The starting dose is provided by the 40 mg divisible tablet.</p><p>The target maximum dose is 160 mg twice daily. In general, it is recommended that patients achieve a dose level of 80 mg twice daily by two weeks after treatment initiation and that the target maximum dose, 160 mg twice daily, be achieved by three months, based on the patient&#39;s tolerability. If symptomatic hypotension or renal dysfunction occur, consideration should be given to a dose reduction.</p><p>Arbaval may be used in patients treated with other post-myocardial infarction therapies,</p><p>e.g. thrombolytics, acetylsalicylic acid, beta blockers, statins, and diuretics. The combination with ACE inhibitors is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of post-myocardial infarction patients should always include assessment of renal function.</p><p>Heart failure (only 40 mg, 80 mg and 160 mg)</p><p>The recommended starting dose of Arbaval is 40 mg twice daily. Uptitration to 80 mg and 160 mg twice daily should be done at intervals of at least two weeks to the highest dose, as tolerated by the patient. Consideration should be given to reducing the dose of concomitant diuretics. The maximum daily dose administered in clinical trials is 320 mg in divided doses.</p><p>Arbaval may be administered with other heart failure therapies. However, the triple combination of an ACE inhibitor, a beta blocker and Arbaval is not recommended (see sections 4.4 and 5.1).</p><p>Evaluation of patients with heart failure should always include assessment of renal function.</p><p>Additional information on special populations Elderly</p><p>No dose adjustment is required in elderly patients. Renal impairment</p><p>No dose adjustment is required for adult patients with a creatinine clearance &gt;10 ml/min (see sections 4.4 and 5.2).</p><p>Hepatic impairment</p><p>Arbaval is contraindicated in patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). In patients with mild to moderate hepatic impairment without cholestasis, the dose of Arbaval should not exceed 80 mg.</p><p>Paediatric population Paediatric hypertension</p><p>Children and adolescents 6 to 18 years of age</p><p>The initial dose is 40 mg once daily for children weighing below 35 kg and 80 mg once daily for those weighing 35 kg or more. The dose should be adjusted based on blood pressure response. For maximum doses studied in clinical trials please refer to the table below.</p><p>Doses higher than those listed have not been studied and are therefore not recommended. Weight&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Maximum dose studied in clinical trials</p><p>&nbsp;</p><p>&ge;18 kg to &lt;35 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 80 mg</p><p>&ge;35 kg to &lt;80 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 160 mg</p><p>&ge;80 kg to &le;160 kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 320 mg</p><p>&nbsp;</p><p>For children who cannot swallow tablets, or children for whom the calculated dosage (mg/kg) does not correspond to the available tablet strengths of Arbaval, the use of a suspension is recommended. Follow the suspension preparation instructions below (see Preparation of Suspension) to administer Valsartan as a suspension. When the suspension is replaced by a tablet, the dose of Valsartan may have to be increased. The exposure to Valsartan with the suspension is 1.6 times greater than with the tablet. No data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate</p><p>&lt;30 mL/min/1.73 m2.</p><p>Preparation of Suspension (for 160 mL of a 4 mg/mL suspension)</p><p>Add 80 mL of Ora-Plus&reg;* oral suspending vehicle to an amber glass bottle containing 8 Arbaval 80 mg tablets, and shake for a minimum of 2 minutes. Allow the suspension to stand for a minimum of 1 hour. After the standing time, shake the suspension for a minimum of 1 additional minute. Add 80 mL of Ora-Sweet SF&reg;* oral sweetening vehicle to the bottle and shake the suspension for at least 10 seconds to disperse the ingredients. The suspension is homogenous and can be stored for either up to 30 days at room temperature (below 30&deg;C/86&deg;F) or up to 75 days at refrigerated conditions (2-8&deg;C/35-46&deg;F) in the glass bottle with a child-resistant screw-cap closure. Shake the bottle well (at least 10 seconds) prior to dispensing the suspension.</p><p>*Ora-Sweet SF&reg; and Ora-Plus&reg; are registered trademarks of Paddock Laboratories, Inc.</p><p>Children less than 6 years of age</p><p>Available data are described in sections 4.8, 5.1 and 5.2. However safety and efficacy of Arbaval in children aged 1 to 6 years have not been established.</p><p>Use in paediatric patients aged 6 to 18 years with renal impairment</p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore Arbaval is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance</p><p>&gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.4 and 5.2).</p><p>Use in paediatric patients aged 6 to 18 years with hepatic impairment</p><p>As in adults, Arbaval is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3, 4.4 and 5.2). There is limited clinical experience with Arbaval in paediatric patients with mild to moderate hepatic impairment. The dose of Arbaval should not exceed 80 mg in these patients.</p><p>Paediatric heart failure and recent myocardial infarction</p><p>Arbaval is not recommended for the treatment of heart failure or recent myocardial infarction in children and adolescents below the age of 18 years due to the lack of data on safety and efficacy.</p><p>Method of administration</p><p>Arbaval may be taken independently of a meal and should be administered with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients.
-	Severe hepatic impairment, biliary cirrhosis and cholestasis.
-	Second and third trimester of pregnancy (see sections 4.4 and 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Hyperkalaemia</p><p>Concomitant use with potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium, or other agents that may increase potassium levels (heparin, etc.) is not recommended. Monitoring of potassium should be undertaken as appropriate.</p><p>Impaired renal function</p><p>There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore Arbaval should be used with caution in these patients. No dose adjustment is required for adult patients with creatinine clearance</p><p>&gt;10 ml/min (see sections 4.2 and 5.2).</p><p>Hepatic impairment</p><p>In patients with mild to moderate hepatic impairment without cholestasis, Arbaval should be used with caution (see sections 4.2 and 5.2).</p><p>Sodium- and/or volume-depleted patients</p><p>In severely sodium-depleted and/or volume-depleted patients, such as those receiving high doses of diuretics, symptomatic hypotension may occur in rare cases after initiation of therapy with Arbaval . Sodium and/or volume depletion should be corrected before starting treatment with Arbaval , for example by reducing the diuretic dose.</p><p>Renal artery stenosis</p><p>In patients with bilateral renal artery stenosis or stenosis to a solitary kidney, the safe use of Arbaval has not been established.</p><p>Short-term administration of Arbaval to twelve patients with renovascular hypertension secondary to unilateral renal artery stenosis did not induce any significant changes in renal haemodynamics, serum creatinine, or blood urea nitrogen (BUN). However, other agents that affect the renin-angiotensin system may increase blood urea and serum creatinine in patients with unilateral renal artery stenosis, therefore monitoring of renal function is recommended when patients are treated with Arbaval .</p><p>Kidney transplantation</p><p>There is currently no experience on the safe use of Arbaval in patients who have recently undergone kidney transplantation.</p><p>Primary hyperaldosteronism</p><p>Patients with primary hyperaldosteronism should not be treated with Arbaval as their renin-angiotensin system is not activated.</p><p>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy</p><p>As with all other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy (HOCM).</p><p>Pregnancy</p><p>Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy. Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established</p><p>&nbsp;</p><p>safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).</p><p>Recent myocardial infarction (only 40 mg, 80 mg and 160 mg)</p><p>The combination of captopril and Arbaval has shown no additional clinical benefit, instead the risk for adverse events increased compared to treatment with the respective therapies (see sections 4.2 and 5.1). Therefore, the combination of Arbaval with an ACE inhibitor is not recommended.</p><p>Caution should be observed when initiating therapy in post-myocardial infarction patients. Evaluation of post-myocardial infarction patients should always include assessment of renal function (see section 4.2).</p><p>Use of Arbaval in post-myocardial infarction patients commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>Heart Failure (only 40 mg, 80 mg and 160 mg)</p><p>In patients with heart failure, the triple combination of an ACE inhibitor, a beta blocker and Arbaval has not shown any clinical benefit (see section 5.1). This combination apparently increases the risk for adverse events and is therefore not recommended.</p><p>Caution should be observed when initiating therapy in patients with heart failure. Evaluation of patients with heart failure should always include assessment of renal function (see section 4.2).</p><p>Use of Arbaval in patients with heart failure commonly results in some reduction in blood pressure, but discontinuation of therapy because of continuing symptomatic hypotension is not usually necessary provided dosing instructions are followed (see section 4.2).</p><p>In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As Arbaval is an angiotensin II antagonist, it cannot be excluded that the use of Arbaval may be associated with impairment of the renal function.</p><p>History of angioedema</p><p>Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, and/or tongue has been reported in patients treated with Arbaval ; some of these patients previously experienced angioedema with other drugs including ACE inhibitors. Arbaval should be immediately discontinued in patients who develop angioedema, and Arbaval should not be re-administered (see section 4.8).</p><p>Other conditions with stimulation of the renin-angiotensin system (only 320 mg)</p><p>In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g patients with severe congestive heart failure), treatment with angiotensin converting enzyme inhibitors has been associated with oliguria and/or progressive azotaemia and in rare cases with acute renal failure and/or death. As Arbaval is an angiotensin II antagonist, it cannot be excluded that the use of Arbaval may be associated with impairment of the renal function.</p><p>&nbsp;</p><p>Paediatric population</p><p>Impaired renal function</p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore Arbaval is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance</p><p>&gt;30 ml/min (see sections 4.2 and 5.2). Renal function and serum potassium should be closely monitored during treatment with Arbaval . This applies particularly when Arbaval is given in the presence of other conditions (fever, dehydration) likely to impair renal function.</p><p>Impaired hepatic function</p><p>As in adults, Arbaval is contraindicated in paediatric patients with severe hepatic impairment, biliary cirrhosis and in patients with cholestasis (see sections 4.3 and 5.2). There is limited clinical experience with Arbaval in paediatric patients with mild to moderate hepatic impairment. The dose of Arbaval should not exceed 80 mg in these patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Concomitant use not recommended</p><p>Lithium</p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concurrent use of ACE inhibitors. Due to the lack of experience with concomitant use of Arbaval and lithium, this combination is not recommended. If the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p>Potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium and other substances that may increase potassium levels</p><p>If a medicinal product that affects potassium levels is considered necessary in combination with Arbaval , monitoring of potassium plasma levels is advised.</p><p>Caution required with concomitant use</p><p><strong>Non-steroidal anti-inflammatory medicines (NSAIDs), </strong>including selective COX-2 inhibitors, acetylsalicylic acid &gt;3 g/day), and non-selective NSAIDs</p><p>When angiotensin II antagonists are administered simultaneously with NSAIDs, attenuation of the antihypertensive effect may occur. Furthermore, concomitant use of angiotensin II antagonists and NSAIDs may lead to an increased risk of worsening of renal function and an increase in serum potassium. Therefore, monitoring of renal function at the beginning of the treatment is recommended, as well as adequate hydration of the patient.</p><p>Transporters</p><p>In vitro data indicates that Arbaval is a substrate of the hepatic uptake transporter OATP1B1/OATP1B3 and the hepatic efflux transporter MRP2. The clinical relevance of this finding is unknown. Co-administration of inhibitors of the uptake transporter (eg. rifampin, ciclosporin) or efflux transporter (eg. ritonavir) may increase the systemic exposure to Arbaval . Exercise appropriate care when initiating or ending concomitant treatment with such drugs.</p><p>Others</p><p>&nbsp;</p><p>In drug interaction studies with Arbaval , no interactions of clinical significance have been found with Arbaval or any of the following substances: cimetidine, warfarin, furosemide, digoxin, atenolol, indometacin, hydrochlorothiazide, amlodipine, glibenclamide.</p><p>Paediatric population</p><p>In hypertension in children and adolescents, where underlying renal abnormalities are common, caution is recommended with the concomitant use of Arbaval and other substances that inhibit the renin angiotensin aldosterone system which may increase serum potassium. Renal function and serum potassium should be closely monitored.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy category (D)</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with AIIRAs, similar risks may exist for this class of drugs. Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>AIIRAs therapy exposure during the second and third trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia); see also section 5.3 &ldquo;Preclinical safety data&rdquo;.</p><p>Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p>Lactation</p><p>Because no information is available regarding the use of Arbaval during breastfeeding, Arbaval is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p>Fertility</p><p>Arbaval had no adverse effects on the reproductive performance of male or female rats at oral doses up to 200 mg/kg/day. This dose is 6 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive have been performed. When driving vehicles or operating machines it should be taken into account that occasionally dizziness or weariness may occur.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>1.1&nbsp;&nbsp; </strong>In controlled clinical studies in adult patients with hypertension, the overall incidence of adverse reactions (ADRs) was comparable with placebo and is consistent with the</p><p>&nbsp;</p><p>pharmacology of Arbaval. The incidence of ADRs did not appear to be related to dose or treatment duration and also showed no association with gender, age or race.</p><p>The ADRs reported from clinical studies, post-marketing experience and laboratory findings are listed below according to system organ class.</p><p>Adverse reactions are ranked by frequency, the most frequent first, using the following</p><p>convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to</p><p>&lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000) very rare (&lt;1/10,000), including isolated reports. Within each frequency grouping, adverse reactions are ranked in order of decreasing seriousness.</p><p>For all the ADRs reported from post-marketing experience and laboratory findings, it is not possible to apply any ADR frequency and therefore they are mentioned with a &quot;not known&quot; frequency.</p><p>-&nbsp; Hypertension</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Decrease in haemoglobin, Decrease in haematocrit, Neutropenia, Thrombocytopenia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Immune system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypersensitivity including serum sickness</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Increase of serum potassium, hyponatraemia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Ear and labyrinth system disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Vascular disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Vasculitis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hepato-biliary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Elevation of liver function values including increase of serum bilirubin</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Angioedema, Rash, Pruritus</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Renal failure and impairment, Elevation of serum creatinine</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fatigue</p></td></tr></tbody></table><p>Paediatric population Hypertension</p><p>The antihypertensive effect of Arbaval has been evaluated in two randomised, double- blind clinical studies in 561 paediatric patients from 6 to 18 years of age. With the exception of isolated gastrointestinal disorders (like abdominal pain, nausea, vomiting) and dizziness, no relevant differences in terms of type, frequency and severity of adverse reactions were identified between the safety profile for paediatric patients aged 6 to 18 years and that previously reported for adult patients.</p><p>Neurocognitive and developmental assessment of paediatric patients aged 6 to 16 years of age revealed no overall clinically relevant adverse impact after treatment with Arbaval for up to one year.</p><p>In a double-blind randomized study in 90 children aged 1 to 6 years, which was followed by a one-year open-label extension, two deaths and isolated cases of marked liver transaminases elevations were observed. These cases occurred in a population who had significant comorbidities. A causal relationship to Arbaval has not been established. In a second study in which 75 children aged 1 to 6 years were randomised, no significant liver transaminase elevations or death occurred with Arbaval treatment.</p><p>Hyperkalaemia was more frequently observed in children and adolescents aged 6 to 18 years with underlying chronic kidney disease.</p><p>The safety profile seen in controlled-clinical studies in adult patients with post-myocardial infarction and/or heart failure varies from the overall safety profile seen in hypertensive patients. This may relate to the patients underlying disease. ADRs that occurred in adult patients with post-myocardial infarction and/or heart failure patients are listed below.</p><p>-Post-myocardial infarction and/or heart failure (studied in adult patients only) Blood and lymphatic system disorders</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia Immune system disorders</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity including serum sickness Metabolism and nutrition disorders</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperkalaemia</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase of serum potassium, hyponatraemia Nervous system disorders</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, Postural dizziness Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syncope, Headache</p><p>Ear and labyrinth system disorders Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo</p><p>&nbsp;</p><p>Cardiac disorders</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cardiac failure Vascular disorders</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension, Orthostatic hypotension Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vasculitis</p><p>Respiratory, thoracic and mediastinal disorders Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>Gastrointestinal disorders Uncommon Nausea, Diarrhoea Hepato-biliary disorders</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevation of liver function values Skin and subcutaneous tissue disorders</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angioedema</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, Pruritis Musculoskeletal and connective tissue disorders Not known Myalgia</p><p>Renal and urinary disorders</p><p>Common&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal failure and impairment</p><p>Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure, Elevation of serum creatinine Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in Blood Urea Nitrogen</p><p>General disorders and administration site conditions Uncommon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthenia, Fatigue</p><p>-&nbsp; To reports any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1027" type="#_x0000_t202" style='width:456.4pt;
 height:88.45pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText align=left style='margin-left:5.15pt;text-align:left;
    line-height:14.6pt;mso-line-height-rule:exactly'>-The<span
    style='letter-spacing:-.15pt'> </span>National Pharmacovigilance and<span
    style='letter-spacing:-.1pt'> </span>Drug<span style='letter-spacing:-.15pt'>
    </span>Safety<span style='letter-spacing:-.25pt'> </span>Centre (NPC)<o:p></o:p></p>
    <p class=MsoBodyText align=left style='margin-top:.1pt;margin-right:0in;
    margin-bottom:0in;margin-left:11.5pt;margin-bottom:.0001pt;text-align:left;
    text-indent:-6.4pt;line-height:13.3pt;mso-line-height-rule:exactly;
    mso-list:l1 level1 lfo1;tab-stops:11.55pt'><![if !supportLists]><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
    dir=LTR></span>SFDA<span style='letter-spacing:-.15pt'> </span>Call<span
    style='letter-spacing:-.15pt'> </span>Center:<span style='letter-spacing:
    -.1pt'> </span>19999<o:p></o:p></p>
    <p class=MsoBodyText align=left style='margin-left:11.5pt;text-align:left;
    text-indent:-6.4pt;line-height:12.0pt;mso-line-height-rule:exactly;
    mso-list:l1 level1 lfo1;tab-stops:11.55pt'><![if !supportLists]><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
    dir=LTR></span>E-mail:<span style='letter-spacing:-.25pt'> </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
    text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
    <p class=MsoBodyText align=left style='margin-left:11.5pt;text-align:left;
    text-indent:-6.4pt;line-height:13.3pt;mso-line-height-rule:exactly;
    mso-list:l1 level1 lfo1;tab-stops:11.55pt'><![if !supportLists]><span
    style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp; </span></span><![endif]><span
    dir=LTR></span>Website:<span style='letter-spacing:-.5pt'> </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='color:windowtext;
    text-decoration:none;text-underline:none'>https://ade.sfda.gov.sa/</span></a><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="615" height="124" alt="Text Box: -The National Pharmacovigilance and Drug Safety Centre (NPC)
-	SFDA Call Center: 19999
-	E-mail: npc.drug@sfda.gov.sa
-	Website: https://ade.sfda.gov.sa/
" src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:456.4pt;height:88.45pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shape id="_x0000_s1026"
 type="#_x0000_t202" style='width:415.8pt;height:15.25pt;mso-left-percent:-10001;
 mso-top-percent:-10001;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:char;mso-position-vertical:absolute;
 mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001'
 filled="f" strokeweight=".48pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText align=left style='margin-top:.1pt;margin-right:0in;
    margin-bottom:0in;margin-left:5.15pt;margin-bottom:.0001pt;text-align:left'>-<span
    style='letter-spacing:-.15pt'> </span>Please<span style='letter-spacing:
    -.15pt'> </span>contact<span style='letter-spacing:-.25pt'> </span>the<span
    style='letter-spacing:-.1pt'> </span>relevant<span style='letter-spacing:
    -.15pt'> </span>competent<span style='letter-spacing:-.1pt'> </span>authority.<o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="561" height="26" alt="Text Box: - Please contact the relevant competent authority." src="file:///C:/Users/AMR~1.MAK/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1026"
 type="#_x0000_t75" style='width:415.8pt;height:15.25pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms</p><p>Overdose with Arbaval may result in marked hypotension, which could lead to depressed level of consciousness, circulatory collapse and/or shock.</p><p>Treatment</p><p>The therapeutic measures depend on the time of ingestion and the type and severity of the symptoms; stabilisation of the circulatory condition is of prime importance.</p><p>If hypotension occurs, the patient should be placed in a supine position and blood volume correction should be undertaken.</p><p>Arbaval is unlikely to be removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II Antagonists, plain, ATC code: C09CA03</p><p>Arbaval is an orally active, potent, and specific angiotensin II (Ang II) receptor antagonist. It acts selectively on the AT1 receptor subtype, which is responsible for the known actions of angiotensin II. The increased plasma levels of Ang II following AT1 receptor blockade with Arbaval may stimulate the unblocked AT2 receptor, which appears to counterbalance the effect of the AT1 receptor. Arbaval does not exhibit any partial agonist activity at the AT1 receptor and has much (about 20,000 fold) greater affinity for the AT1 receptor than for the AT2 receptor. Arbaval is not known to bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.</p><p>Arbaval does not inhibit ACE (also known as kininase II) which converts Ang I to Ang II and degrades bradykinin. Since there is no effect on ACE and no potentiation of bradykinin or substance P, angiotensin II antagonists are unlikely to be associated with coughing. In clinical trials where Arbaval was compared with an ACE inhibitor, the incidence of dry cough was significantly (p&lt;0.05) less in patients treated with Arbaval than in those treated with an ACE inhibitor (2.6% versus 7.9% respectively). In a clinical trial of patients with a history of dry cough during ACE inhibitor therapy, 19.5% of trial subjects receiving Arbaval and 19.0% of those receiving a thiazide diuretic experienced cough compared to 68.5% of those treated with an ACE inhibitor (p&lt;0.05).</p><p>Hypertension (only 80 mg, 160 mg and 320 mg)</p><p>Administration of Arbaval to patients with hypertension results in reduction of blood pressure without affecting pulse rate.</p><p>In most patients, after administration of a single oral dose, onset of antihypertensive activity occurs within 2 hours, and the peak reduction of blood pressure is achieved within 4-6 hours. The antihypertensive effect persists over 24 hours after dosing. During repeated dosing, the antihypertensive effect is substantially present within 2 weeks, and maximal effects are attained within 4 weeks and persist during long-term therapy. Combined with hydrochlorothiazide, a significant additional reduction in blood pressure is achieved.</p><p>Abrupt withdrawal of Arbaval has not been associated with rebound hypertension or other adverse clinical events.</p><p>In hypertensive patients with type 2 diabetes and microalbuminuria, Arbaval has been shown to reduce the urinary excretion of albumin. The MARVAL (Micro Albuminuria Reduction with Arbaval ) study assessed the reduction in urinary albumin excretion (UAE) with Arbaval (80-160 mg/od) versus amlodipine (5-10 mg/od), in 332 type 2 diabetic patients (mean age: 58 years; 265 men) with microalbuminuria (Arbaval : 58 &micro;g/min; amlodipine: 55.4 &micro;g/min), normal or high blood pressure and with preserved renal function (blood creatinine &lt;120 &micro;mol/l). At 24 weeks, UAE was reduced (p&lt;0.001) by 42% (&ndash;24.2 &micro;g/min; 95% CI: &ndash;40.4 to &ndash;19.1) with Arbaval and approximately 3% (&ndash;1.7 &micro;g/min; 95% CI:</p><p>&ndash;5.6 to 14.9) with amlodipine despite similar rates of blood pressure reduction in both groups.</p><p>The Arbaval Reduction of Proteinuria (DROP) study further examined the efficacy of Arbaval in reducing UAE in 391 hypertensive patients (BP=150/88 mmHg) with type 2</p><p>&nbsp;</p><p>diabetes, albuminuria (mean=102 &micro;g/min; 20-700 &micro;g/min) and preserved renal function (mean serum creatinine = 80 &micro;mol/l). Patients were randomized to one of 3 doses of Arbaval (160, 320 and 640 mg/od) and treated for 30 weeks. The purpose of the study was to determine the optimal dose of Arbaval for reducing UAE in hypertensive patients with type 2 diabetes. At 30 weeks, the percentage change in UAE was significantly reduced by 36% from baseline with Arbaval 160 mg (95%CI: 22 to 47%), and by 44% with Arbaval 320 mg (95%CI: 31 to 54%). It was concluded that 160-320 mg of Arbaval produced clinically relevant reductions in UAE in hypertensive patients with type 2 diabetes.</p><p>Recent myocardial infarction (only 40 mg, 80 mg and 160 mg)</p><p>The Arbaval In Acute myocardial iNfarcTion trial (VALIANT) was a randomised, controlled, multinational, double-blind study in 14,703 patients with acute myocardial infarction and signs, symptoms or radiological evidence of congestive heart failure and/or evidence of left ventricular systolic dysfunction (manifested as an ejection fraction &le;40% by radionuclide ventriculography or &le;35% by echocardiography or ventricular contrast angiography). Patients were randomised within 12 hours to 10 days after the onset of myocardial infarction symptoms to Arbaval , captopril, or the combination of both. The mean treatment duration was two years. The primary endpoint was time to all-cause mortality.</p><p>Arbaval was as effective as captopril in reducing all-cause mortality after myocardial infarction. All-cause mortality was similar in the Arbaval (19.9%), captopril (19.5%), and Arbaval + captopril (19.3%) groups. Combining Arbaval with captopril did not add further benefit over captopril alone. There was no difference between Arbaval and captopril in all- cause mortality based on age, gender, race, baseline therapies or underlying disease. Arbaval was also effective in prolonging the time to and reducing cardiovascular mortality, hospitalisation for heart failure, recurrent myocardial infarction, resuscitated cardiac arrest, and non-fatal stroke (secondary composite endpoint).</p><p>The safety profile of Arbaval was consistent with the clinical course of patients treated in the post-myocardial infarction setting. Regarding renal function, doubling of serum creatinine was observed in 4.2% of Arbaval -treated patients, 4.8% of Arbaval +captopril- treated patients, and 3.4% of captopril-treated patients. Discontinuations due to various types of renal dysfunction occurred in 1.1% of Arbaval -treated patients, 1.3% in Arbaval</p><p>+captopril patients, and 0.8% of captopril patients. An assessment of renal function should be included in the evaluation of patients post-myocardial infarction.</p><p>There was no difference in all-cause mortality, cardiovascular mortality or morbidity when beta blockers were administered together with the combination of Arbaval + captopril, Arbaval alone, or captopril alone. Irrespective of treatment, mortality was lower in the group of patients treated with a beta blocker, suggesting that the known beta blocker benefit in this population was maintained in this trial.</p><p>Heart failure (only 40 mg, 80 mg and 160 mg)</p><p>Val-HeFT was a randomised, controlled, multinational clinical trial of Arbaval compared with placebo on morbidity and mortality in 5,010 NYHA class II (62%), III (36%) and IV (2%) heart failure patients receiving usual therapy with LVEF &lt;40% and left ventricular internal diastolic diameter (LVIDD) &gt;2.9 cm/m2. Baseline therapy included ACE inhibitors (93%), diuretics (86%), digoxin (67%) and beta blockers (36%). The mean duration of follow-up was nearly two years. The mean daily dose of Arbaval in Val-HeFT was 254 mg. The study</p><p>&nbsp;</p><p>had two primary endpoints: all cause mortality (time to death) and composite mortality and heart failure morbidity (time to first morbid event) defined as death, sudden death with resuscitation, hospitalisation for heart failure, or administration of intravenous inotropic or vasodilator agents for four hours or more without hospitalisation.</p><p>All cause mortality was similar (p=NS) in the Arbaval (19.7%) and placebo (19.4%) groups. The primary benefit was a 27.5% (95% CI: 17 to 37%) reduction in risk for time to first heart failure hospitalisation (13.9% vs. 18.5%). Results appearing to favour placebo (composite mortality and morbidity was 21.9% in placebo vs. 25.4% in Arbaval group) were observed for those patients receiving the triple combination of an ACE inhibitor, a beta blocker and Arbaval .</p><p>In a subgroup of patients not receiving an ACE inhibitor (n=366), the morbidity benefits were greatest. In this subgroup all-cause mortality was significantly reduced with Arbaval compared to placebo by 33% (95% CI: &ndash;6% to 58%) (17.3% Arbaval vs. 27.1% placebo) and the composite mortality and morbidity risk was significantly reduced by 44% (24.9% Arbaval vs. 42.5% placebo).</p><p>In patients receiving an ACE inhibitor without a beta-blocker, all cause mortality was similar (p=NS) in the Arbaval (21.8%) and placebo (22.5%) groups. Composite mortality and morbidity risk was significantly reduced by 18.3% (95% CI: 8% to 28%) with Arbaval compared with placebo (31.0% vs. 36.3%).</p><p>In the overall Val-HeFT population, Arbaval treated patients showed significant improvement in NYHA class, and heart failure signs and symptoms, including dyspnoea, fatigue, oedema and rales compared to placebo. Patients treated with Arbaval&nbsp;&nbsp; had a better quality of life as demonstrated by change in the Minnesota Living with Heart Failure Quality of Life score from baseline at endpoint than placebo. Ejection fraction in Arbaval treated patients was significantly increased and LVIDD significantly reduced from baseline at endpoint compared to placebo.</p><p>Paediatric population Hypertension</p><p>The antihypertensive effect of Arbaval have been evaluated in four randomized, double- blind clinical studies in 561 paediatric patients from 6 to 18 years of age and 165 paediatric patients 1 to 6 years of age. Renal and urinary disorders and obesity were the most common underlying medical conditions potentially contributing to hypertension in the children enrolled in these studies.</p><p>Clinical experience in children at or above 6 years of age</p><p>In a clinical study involving 261 hypertensive paediatric patients 6 to 16 years of age, patients who weighed &lt;35 kg received 10, 40 or 80 mg of Arbaval tablets daily (low, medium and high doses), and patients who weighed &ge;35 kg received 20, 80, and 160 mg of Arbaval tablets daily (low, medium and high doses). At the end of 2 weeks, Arbaval reduced both systolic and diastolic blood pressure in a dose-dependent manner. Overall, the three dose levels of Arbaval (low, medium and high) significantly reduced systolic blood pressure by 8, 10, 12 mm Hg from the baseline, respectively. Patients were re- randomized to either continue receiving the same dose of Arbaval or were switched to placebo. In patients who continued to receive the medium and high doses of Arbaval , systolic blood pressure at trough was -4 and -7 mm Hg lower than patients who received</p><p>&nbsp;</p><p>the placebo treatment. In patients receiving the low dose of Arbaval, systolic blood pressure at trough was similar to that of patients who received the placebo treatment. Overall, the dose-dependent antihypertensive effect of Arbaval was consistent across all the demographic subgroups.</p><p>In another clinical study involving 300 hypertensive paediatric patients 6 to 18 years of age, eligible patients were randomized to receive Arbaval or enalapril tablets for 12 weeks. Children weighing between &ge;18 kg and &lt;35 kg received Arbaval 80 mg or enalapril 10 mg; those between &ge;35 kg and &lt;80 kg received Arbaval 160 mg or enalapril 20 mg; those &ge;80 kg received Arbaval 320 mg or enalapril 40 mg. Reductions in systolic blood pressure were comparable in patients receiving Arbaval (15 mmHg) and enalapril (14 mm Hg) (non- inferiority p-value &lt;0.0001). Consistent results were observed for diastolic blood pressure with reductions of 9.1 mmHg and 8.5 mmHg with Arbaval and enalapril, respectively.</p><p>Clinical experience in children less than 6 years of age</p><p>Two clinical studies were conducted in patients aged 1 to 6 years with 90 and 75 patients, respectively. No children below the age of 1 year were enrolled in these studies. In the first study, the efficacy of Arbaval was confirmed compared to placebo but a dose-response could not be demonstrated. In the second study, higher doses of Arbaval were associated with greater BP reductions, but the dose response trend did not achieve statistical significance and the treatment difference compared to placebo was not significant. Because of these inconsistencies, Arbaval is not recommended in this age group (see section 4.8).</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Arbaval in all subsets of the paediatric population in heart failure and heart failure after recent myocardial infarction. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption:</p><p>Following oral administration of Arbaval alone, peak plasma concentrations of Arbaval are reached in 2&ndash;4 hours with tablets and 1&ndash;2 hours with solution formulation. Mean absolute bioavailability is 23% and 39% with tablets and solution formulation, respectively. Food decreases exposure (as measured by AUC) to Arbaval by about 40% and peak plasma concentration (Cmax) by about 50%, although from about 8 h post dosing plasma Arbaval concentrations are similar for the fed and fasted groups. This reduction in AUC is not, however, accompanied by a clinically significant reduction in the therapeutic effect, and Arbaval can therefore be given either with or without food.</p><p>Distribution:</p><p>The steady-state volume of distribution of Arbaval after intravenous administration is about 17 litres, indicating that Arbaval does not distribute into tissues extensively. Arbaval is highly bound to serum proteins (94&ndash;97%), mainly serum albumin.</p><p>Biotransformation:</p><p>Arbaval is not biotransformed to a high extent as only about 20% of dose is recovered as metabolites. A hydroxy metabolite has been identified in plasma at low concentrations (less than 10% of the Arbaval AUC). This metabolite is pharmacologically inactive.</p><p>Excretion:</p><p>&nbsp;</p><p>Arbaval shows multiexponential decay kinetics (t&frac12;&alpha; &lt;1 h and t&frac12;&szlig; about 9 h). Arbaval is primarily eliminated by biliary excretion in faeces (about 83% of dose) and renally in urine (about 13% of dose), mainly as unchanged drug. Following intravenous administration, plasma clearance of Arbaval is about 2 l/h and its renal clearance is 0.62 l/h (about 30% of total clearance). The half-life of Arbaval is 6 hours.</p><p>In heart failure patients (only 40 mg, 80 mg and 160 mg):</p><p>The average time to peak concentration and elimination half-life of Arbaval in heart failure patients are similar to that observed in healthy volunteers. AUC and Cmax values of Arbaval are almost proportional with increasing dose over the clinical dosing range (40 to 160 mg twice a day). The average accumulation factor is about 1.7. The apparent clearance of Arbaval following oral administration is approximately 4.5 l/h. Age does not affect the apparent clearance in heart failure patients.</p><p>Special populations Elderly</p><p>A somewhat higher systemic exposure to Arbaval was observed in some elderly subjects than in young subjects; however, this has not been shown to have any clinical significance. Impaired renal function</p><p>As expected for a compound where renal clearance accounts for only 30% of total plasma clearance, no correlation was seen between renal function and systemic exposure to Arbaval . Dose adjustment is therefore not required in patients with renal impairment (creatinine clearance &gt;10 ml/min). There is currently no experience on the safe use in patients with a creatinine clearance &lt;10 ml/min and patients undergoing dialysis, therefore Arbaval should be used with caution in these patients (see sections 4.2 and 4.4).</p><p>Arbaval is highly bound to plasma protein and is unlikely to be removed by dialysis. Hepatic impairment</p><p>Approximately 70% of the dose absorbed is eliminated in the bile, essentially in the unchanged form. Arbaval does not undergo any noteworthy biotransformation. A doubling of exposure (AUC) was observed in patients with mild to moderate hepatic impairment compared to healthy subjects. However, no correlation was observed between plasma Arbaval concentration versus degree of hepatic dysfunction. Arbaval has not been studied in patients with severe hepatic dysfunction (see sections 4.2, 4.3 and 4.4).</p><p>Paediatric population</p><p>In a study of 26 paediatric hypertensive patients (aged 1 to 16 years) given a single dose of a suspension of Arbaval (mean: 0.9 to 2 mg/kg, with a maximum dose of 80 mg), the clearance (litres/h/kg) of Arbaval&nbsp;&nbsp; was comparable across the age range of 1 to 16 years and similar to that of adults receiving the same formulation.</p><p>Impaired renal function</p><p>Use in paediatric patients with a creatinine clearance &lt;30 ml/min and paediatric patients undergoing dialysis has not been studied, therefore Arbaval is not recommended in these patients. No dose adjustment is required for paediatric patients with a creatinine clearance</p><p>&gt;30 ml/min. Renal function and serum potassium should be closely monitored (see sections 4.2 and 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential.</p><p>In rats, maternally toxic doses (600 mg/kg/day) during the last days of gestation and lactation led to lower survival, lower weight gain and delayed development (pinna detachment and ear-canal opening) in the offspring (see section 4.6). These doses in rats (600 mg/kg/day) are approximately 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In non-clinical safety studies, high doses of Arbaval (200 to 600 mg/kg body weight) caused in rats a reduction of red blood cell parameters (erythrocytes, haemoglobin, haematocrit) and evidence of changes in renal haemodynamics (slightly raised plasma urea, and renal tubular hyperplasia and basophilia in males). These doses in rats (200 and 600 mg/kg/day) are approximately 6 and 18 times the maximum recommended human dose on a mg/m2 basis (calculations assume an oral dose of 320 mg/day and a 60-kg patient).</p><p>In marmosets at similar doses, the changes were similar though more severe, particularly in the kidney where the changes developed to a nephropathy which included raised urea and creatinine.</p><p>Hypertrophy of the renal juxtaglomerular cells was also seen in both species. All changes were considered to be caused by the pharmacological action of Arbaval which produces prolonged hypotension, particularly in marmosets. For therapeutic doses of Arbaval in humans, the hypertrophy of the renal juxtaglomerular cells does not seem to have any relevance.</p><p>Paediatric population</p><p>Daily oral dosing of neonatal/juvenile rats (from a postnatal day 7 to postnatal day 70) with Arbaval at doses as low as 1 mg/kg/day (about 10-35% of the maximum recommended paediatric dose of 4 mg/kg/day on systemic exposure basis) produced persistent, irreversible kidney damage. These effects above mentioned represent an expected exaggerated pharmacological effect of angiotensin converting enzyme inhibitors and angiotensin II type 1 blockers; such effects are observed if rats are treated during the first 13 days of life. This period coincides with 36 weeks of gestation in humans, which could occasionally extend up to 44 weeks after conception in humans. The rats in the juvenile Arbaval study were dosed up to day 70, and effects on renal maturation (postnatal 4-6 weeks) cannot be excluded. Functional renal maturation is an ongoing process within the first year of life in humans. Consequently, a clinical relevance in children &lt;1 year of age cannot be excluded, while preclinical data do not indicate a safety concern for children older than 1 year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Silicified microcrystalline cellulose, Crospovidone, Magnesium stearate.<br />The tablet coating contains hypromellose, PEG 4000, Talc, Titanium dioxide, Red iron oxide,<br />Yellow Iron oxide, Carmoisine, and FD&amp;C Blue #2 Aluminum Lake<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.<br />Store in the original package in order to protect from moisture.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Forming Aluminium / Aluminium blister pack<br />Pack sizes: 28 film-coated tablets<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SAJA Pharmaceuticals
Saudi Arabian Japanese pharmaceutical company limited
Jeddah – Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July /2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>